Synthetic biology techniques have emerged as transformative tools in the tug-of-war between humans and drug-resistant ...

Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the ...

With the rapid development of antibiotics in the 1930s, phage therapy – using viruses known as bacteriophages or phages to tackle bacterial infections – fell into oblivion.

which has already shown promise in the treatment of urinary tract infections (UTIs) caused by resistant E coli. Bacteriophages are viruses that solely and selectively target and kill bacteria and ...

Urinary tract infections (UTIs), particularly a type called cystitis, are a painful and common issue that affects half of all ...

Hope that bacteriophages could represent a new therapeutic ... as they show evidence of efficacy with a short seven-day duration of treatment, as well as the safety and tolerability of BX004.

Researchers have enabled the effective selection of phages based on the genome of the bacteria they want to target, helping ...

Despite dealing with drug-resistant infections herself since birth and being fully aware of the looming danger of running out of options to treat the infections, it is indeed inspiring to see ...

(NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage ... AP-SA02 as a potential treatment for Staphylococcus aureus ...

Pathogens have distinct electrical charges, shapes and sizes. Measuring how quickly they move through an electric field can ...